GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Piotroski F-Score

Biomea Fusion (Biomea Fusion) Piotroski F-Score : 2 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biomea Fusion has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Biomea Fusion's Piotroski F-Score or its related term are showing as below:

BMEA' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 3
Current: 2

During the past 5 years, the highest Piotroski F-Score of Biomea Fusion was 3. The lowest was 2. And the median was 2.


Biomea Fusion Piotroski F-Score Historical Data

The historical data trend for Biomea Fusion's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Piotroski F-Score Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 2.00 3.00 2.00

Biomea Fusion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 1.00 2.00 2.00

Competitive Comparison of Biomea Fusion's Piotroski F-Score

For the Biotechnology subindustry, Biomea Fusion's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -29.051 + -24.891 + -28.429 + -34.884 = $-117.26 Mil.
Cash Flow from Operations was -24.044 + -25.812 + -23.899 + -22.837 = $-96.59 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(129.307 + 112.638 + 248.674 + 225.087 + 199.927) / 5 = $183.1266 Mil.
Total Assets at the begining of this year (Dec22) was $129.31 Mil.
Long-Term Debt & Capital Lease Obligation was $7.83 Mil.
Total Current Assets was $179.18 Mil.
Total Current Liabilities was $22.86 Mil.
Net Income was -16.366 + -17.258 + -22.89 + -25.314 = $-81.83 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(185.705 + 174.864 + 161.736 + 145.05 + 129.307) / 5 = $159.3324 Mil.
Total Assets at the begining of last year (Dec21) was $185.71 Mil.
Long-Term Debt & Capital Lease Obligation was $1.67 Mil.
Total Current Assets was $117.82 Mil.
Total Current Liabilities was $19.10 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biomea Fusion's current Net Income (TTM) was -117.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biomea Fusion's current Cash Flow from Operations (TTM) was -96.59. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-117.255/129.307
=-0.90679546

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-81.828/185.705
=-0.44063434

Biomea Fusion's return on assets of this year was -0.90679546. Biomea Fusion's return on assets of last year was -0.44063434. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biomea Fusion's current Net Income (TTM) was -117.26. Biomea Fusion's current Cash Flow from Operations (TTM) was -96.59. ==> -96.59 > -117.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=7.83/183.1266
=0.04275731

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.667/159.3324
=0.0104624

Biomea Fusion's gearing of this year was 0.04275731. Biomea Fusion's gearing of last year was 0.0104624. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=179.181/22.86
=7.83818898

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=117.819/19.101
=6.16821109

Biomea Fusion's current ratio of this year was 7.83818898. Biomea Fusion's current ratio of last year was 6.16821109. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biomea Fusion's number of shares in issue this year was 35.772. Biomea Fusion's number of shares in issue last year was 29.443. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Biomea Fusion's gross margin of this year was . Biomea Fusion's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/129.307
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/185.705
=0

Biomea Fusion's asset turnover of this year was 0. Biomea Fusion's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biomea Fusion has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Biomea Fusion  (NAS:BMEA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biomea Fusion Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomea Fusion (Biomea Fusion) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Executives
Juan Pablo Frias officer: Chief Medical Officer 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc. 10 percent owner 59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m. director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle officer: Chief Financial Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust director C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann director, 10 percent owner, officer: President and COO 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler director, 10 percent owner, officer: CEO 726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc 10 percent owner 726 MAIN STREET, REDWOOD CITY CA 94063

Biomea Fusion (Biomea Fusion) Headlines

From GuruFocus